{"filings":[{"id":93483,"accession_number":"0001437749-26-015590","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q1 net loss $4.0M; PH-762 Phase 1b trial complete with favorable safety","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $17M at March 31, 2026; 2025 equity financings netted ~$23.7M, extending cash runway into H1 2027.","R&D expenses $2.8M (+215% YoY) driven by PH-762 clinical trial, CMC and toxicology costs.","G&A expenses $1.4M (+39% YoY) on higher employee costs, investor outreach and professional fees.","PH-762 dose-escalation study (22 patients) complete; final data being analyzed; FDA submission for next steps targeted Q2 2026.","ATM agreement with H.C. Wainwright in April 2026 allows up to $6.36M in common stock sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93482,"accession_number":"0001437749-26-011761","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.","H.C. Wainwright receives a 3.0% commission on gross proceeds; company reimburses up to $75,000 in legal fees.","No obligation to sell any shares; sales are made on Nasdaq Capital Market with T+1 settlement.","Company provides customary indemnification to the sales agent under the agreement.","The offering is registered under the company's existing S-3 shelf registration statement effective July 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105144,"accession_number":"0001437749-26-010164","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phio signs cGMP manufacturing deal; PH-762 Phase 1b shows 85% pathological response","event_type":"other_material","confidence":"high","bullets":["Entered cGMP drug product manufacturing agreement with U.S. manufacturer for clinical and commercial supply of PH-762.","PH-762 Phase 1b trial: 22 patients completed, no dose-limiting toxicities or serious adverse events.","Pathological response rate across all cohorts ~65%; highest-dose cohort achieved 85% (6 of 7 patients).","FDA engagement for next-stage clinical development targeted for Q2 2026.","Cash and equivalents projected to sustain operations into H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105143,"accession_number":"0001437749-26-007071","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma reports 2025 net loss $8.7M; PH-762 Phase 1b dose escalation complete with favorable data","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.7M ($1.45 EPS) for 2025 vs $7.2M ($9.08 EPS) in 2024; R&D expenses up 27%.","Cash at Dec 31, 2025: $21.0M vs $5.4M year ago; net proceeds from 2025 financings of $20.6M extend runway into H1 2027.","PH-762 Phase 1b dose escalation trial fully enrolled (22 patients); final cohort shows favorable safety, tolerability and pathology.","FDA submission seeking guidance on next steps for PH-762 targeted for Q2 2026; patent portfolio includes 54 issued patents.","Phio entered drug substance development agreement with US manufacturer and toxicology study agreement with US lab in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105142,"accession_number":"0001437749-26-004542","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-02-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals amends CEO Bitterman's contract: severance to 12 months, bonus target to 50%","event_type":"leadership","confidence":"high","bullets":["CEO Robert J. Bitterman's severance increased to 12 months base salary on termination without cause or for good reason.","Annual target bonus opportunity raised from 40% to 50% of base salary.","Amendment effective Feb 17, 2026; equity vesting acceleration unchanged.","No other changes to existing employment agreement terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105141,"accession_number":"0001437749-26-003575","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports 85% pathological response in highest dose cohort of PH-762 Phase 1b trial; no serious adverse events","event_type":"other_material","confidence":"high","bullets":["No serious adverse events or dose-limiting toxicities across all 22 patients in five dose cohorts.","85% pathological response (6/7 patients) in final cohort; 4 of 6 responders had complete tumor clearance.","Overall response rate of 65% for squamous cell carcinomas (13/20 pathologic responders, including 9 complete).","FDA submission for next-step guidance targeted for Q2 2026; cGMP manufacturing expected in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105140,"accession_number":"0001437749-26-001500","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports 70% ORR in cSCC from PH-762 trial; 10 of 14 responders had 100% clearance","event_type":"other_material","confidence":"high","bullets":["22 cutaneous carcinoma patients treated across 5 dose cohorts; no dose-limiting toxicities reported.","Among 20 cSCC patients, 14 responders; 10 complete (100% clearance), 2 major/near clear, 2 partial.","PH-762 well tolerated with 20-fold dose escalation; safety follow-up data expected in Q2 2026.","One Merkel cell carcinoma patient had partial response; no disease progression in any patient."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121397,"accession_number":"0001437749-25-038607","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026","event_type":"regulatory","confidence":"high","bullets":["FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.","Interim Phase 1b results: 6 complete responses among 16 evaluable cSCC patients; no dose-limiting toxicities.","Company advancing cGMP drug product delivery in 2026, partially funded by recent financing.","PH-762 well tolerated in all enrolled patients across five dose cohorts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121396,"accession_number":"0001437749-25-036329","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio completes enrollment in Phase 1b trial of PH-762; positive pathologic responses","event_type":"other_material","confidence":"high","bullets":["18 patients treated across 5 dose cohorts; 16 with cSCC, 1 Merkel cell, 1 melanoma.","cSCC responses: 6 complete (100% clearance), 2 near complete (>90%), 2 partial (>50%).","Merkel cell patient had partial response (>50% clearance); no patients showed disease progression.","No dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported.","Highest dose cohort still enrolling; pathology results expected Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121395,"accession_number":"0001437749-25-034848","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q3 net loss $2.4M; PH-762 trial 100% tumor clearance at max dose","event_type":"earnings","confidence":"high","bullets":["Net loss $2.4M for Q3 2025 vs $1.5M in Q3 2024; R&D expenses $1.2M, G&A $1.3M.","Phase 1b PH-762 trial: 100% tumor clearance (complete response) in one patient at max dose, >90% in second, >50% in third.","Cumulative pathologic results in 16 cSCC patients: 6 complete, 2 near complete, 2 partial responses; no dose-limiting toxicities.","November 2025 warrant inducement financing expected to raise ~$12.1M, extending cash runway into first half 2027.","Cash and equivalents $10.7M at Sep 30, 2025; estimated $21.3M as of release date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121394,"accession_number":"0001437749-25-033600","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio raises ~$13.4M via warrant exercise inducement; issues new warrants for 11.3M shares","event_type":"other_material","confidence":"high","bullets":["Entered inducement agreements for exercise of 5,663,182 existing warrants at reduced prices; gross proceeds ~$13.4M.","First closings Nov 4 & 6 generated ~$12.6M; second expected by Nov 18 for remaining 350,000 warrants.","Issued new unregistered Series A warrants to purchase up to 11,326,364 shares at $2.05, 24-month term.","Proceeds to fund working capital and accelerate development of PH-762 for cutaneous carcinomas.","H.C. Wainwright acting as placement agent; fees include 7.5% cash fee and placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121393,"accession_number":"0001437749-25-032662","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharma: INTASYL PH-762 shows 100% tumor clearance in one cSCC patient; SMC clearance safe","event_type":"other_material","confidence":"high","bullets":["100% pathologic complete response in 1 of 3 cSCC patients at Day 36 in final dose cohort; >90% clearance in second, >50% in third.","Safety Monitoring Committee issued favorable review, no dose-limiting toxicities at max dose; PH-762 well tolerated across 5 cohorts.","Cumulative Phase 1b data: 6 complete, 2 near-complete, 2 partial responses among 16 cSCC patients; no clinical progression.","CEO notes PH-762 is promising non-surgical alternative for cutaneous carcinomas; trial continues to screen additional patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121392,"accession_number":"0001437749-25-032512","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-10-31T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Director Robert Ferrara resigns; David Deming appointed Lead Independent Director","event_type":"leadership","confidence":"high","bullets":["Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.","Board reduced from 6 to 5 members; no vacancies remain.","David Deming appointed Lead Independent Director; brings 30+ yrs investment banking (JP Morgan).","Deming joined Phio Board in Feb 2025; serves on Nominating Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138052,"accession_number":"0001683168-25-006985","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Phio stockholders approve 950,000-share increase to 2020 LTIP plan; adopt 3-year say-on-pay frequency","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected with 84-94% of votes cast; 1,828,465 broker non-votes.","Grant Thornton ratified as auditor for FY2025 with 2,330,465 votes for, 40,532 against.","2020 Plan amendment approved with 387,895 for, 152,069 against; shares available increased to 1,023,017.","Non-binding say-on-pay passed with 474,987 for (87% of votes cast).","Stockholders preferred 3-year say-on-pay frequency (276,177 votes); board adopted triennial vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138051,"accession_number":"0001683168-25-006641","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio advances Phase 1b skin cancer trial to 5th cohort; presents at conference","event_type":"other_material","confidence":"medium","bullets":["Patients are now being treated in the 5th cohort of the ongoing Phase 1b clinical trial for skin cancer (PH-762).","Phio Pharmaceuticals will present at H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025.","CEO Robert Bitterman will deliver an update on the trial and discuss strategy and next steps for the PH-762 program."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138050,"accession_number":"0001683168-25-006171","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Phio Pharma Q2 net loss $2.2M; advances PH-762 Phase 1b to 5th cohort","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M for Q2 2025 vs $1.8M in Q2 2024; cash $10.8M at June 30, 2025.","PH-762 Phase 1b trial: 15 patients treated, 5 complete responses in cSCC; enrolling final 5th cohort.","July 2025 warrant inducement raised ~$2.2M from exercise of existing warrants.","R&D expenses $1.1M in Q2 2025, up from $0.9M YoY due to enrollment costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138049,"accession_number":"0001683168-25-005523","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Phio Pharma receives ~$2.5M from warrant exercise, issues new warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.5M from exercise of 928,596 warrants at $2.00 and $2.485 per share.","Holders issued new unregistered Series J (5-yr term) and Series K (24-mo term) warrants for up to 1,857,192 shares at $2.485/share.","Holders paid additional $0.125 per new warrant ($232,149 aggregate) as part of inducement.","H.C. Wainwright receives 7.5% cash fee and placement agent warrants for 69,645 shares.","Net proceeds to be used for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138048,"accession_number":"0001683168-25-005392","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio reports complete response in cSCC and manufacturing agreement for PH-762","event_type":"other_material","confidence":"high","bullets":["Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.","Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.","One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.","No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.","Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138047,"accession_number":"0001683168-25-004948","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Phio sets 2025 annual meeting for Sept 11; new proposal deadlines","event_type":"other","confidence":"high","bullets":["Annual meeting on Sept 11, 2025; record date July 18, 2025.","Rule 14a-8 stockholder proposals must be received by July 17, 2025.","Director nominations and other proposals not in proxy materials also due July 17, 2025.","Meeting date moved >30 days from 2024 anniversary, triggering revised deadlines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155460,"accession_number":"0001683168-25-004759","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Phio Pharmaceuticals gets SMC nod to advance PH-762 skin cancer trial to fifth cohort","event_type":"other_material","confidence":"high","bullets":["Safety Monitoring Committee recommends dose escalation to fifth (final) cohort in Phase 1b trial of INTASYL PH-762.","No dose-limiting toxicities, serious adverse events, or clinically relevant treatment-emergent reactions in fourth cohort (5 patients).","To date, 15 patients treated; pathological complete response (100% clearance) seen in 4 of 9 cSCC patients from prior cohorts.","Enrollment in final cohort expected to complete in Q3 2025.","PH-762 is an intratumoral siRNA targeting cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155459,"accession_number":"0001683168-25-004421","cik":1533040,"company_name":"Phio Pharmaceuticals Corp.","ticker":"PHIO","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Phio Pharmaceuticals appoints Lisa Carson as CFO/PAO; Infarinato shifts to VP Strategic Development","event_type":"leadership","confidence":"high","bullets":["Lisa Carson named VP Finance and Administration and designated principal financial and accounting officer, effective June 6, 2025.","Robert Infarinato ceased as PFO/PAO, appointed VP Strategic Development effective June 9 to focus on INTASYL portfolio business development.","Carson's compensation: $290k base salary, up to 30% annual bonus, $25k sign-on stipend; at-will employment.","Company announces strategic initiative to raise awareness of INTASYL siRNA portfolio (~30 compounds); positive interim Phase 1b results for PH-762 in skin cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}